European Journal of Heart Failure

MARCH 19, 2025

Semaglutide reduces late sodium current (I Na ) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end-stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients. However, the exact mechanisms underlying its cardioprotective actions remain unclear.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Stenosis Aortic 40

DAIC

FEBRUARY 29, 2024

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Cardiology Update

APRIL 9, 2024

SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Key Takeaways: Natriuretic Peptides : Useful for diagnosing and monitoring heart failure, particularly HFrEF, but challenging to interpret in patients with obesity due to peptide deficiency. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103